|
Angle PLC on Wednesday released successful results from its new dual circulating tumour DNA and circulating tumour cell DNA workflow, using Illumina Inc’s sequencing technology for the first time. The Guildford, England-based cancer research company said the study, conducted in 27 lung cancer patients, showed that CTCs provided additional biomarkers not found in ctDNA from a single blood sample. This suggests that analysing both CTC-DNA and ctDNA could double the number of detected cancer mutations, improving biomarker identification for treatment decisions. Shares in Angle were up 14% at 15.08 pence in London on Wednesday afternoon. In patients who had not received treatment, 100% had mutations detected in CTC-DNA but not in ctDNA. In those currently or previously treated, 90% had mutations found only in CTC-DNA. Some mutations were also identified in ctDNA alone, reinforcing the value of dual analysis for a more comprehensive cancer profile. As a result of these findings, Illumina has dedicated an entire European Association for Cancer Research webinar to Angle’s results, scheduled for February 6. Chief Scientific Officer Karen Miller said: ‘We are excited at the prospect of combining Angle’s Parsortix system with Illumina’s NGS assays and optimising a workflow that will enable Illumina customers to offer CTC analysis in the future. ‘Furthermore, as our research has previously shown, simultaneous analysis of CTCs and ctDNA from the same tube of blood significantly expands the potential for liquid biopsy research and clinical drug discovery and development.’ Chief Executive Andrew Newland added: ‘We see a substantial opportunity for both Angle and Illumina to work closely together and are grateful to Illumina for the opportunity to present our DNA dual analysis data at their webinar hosted by the highly rated EACR.’ Copyright 2025 Alliance News Ltd. All Rights reserved.
|
